Selling pressure pushes Moderna stock lower in today's trading

Traders Union
All News
Financial News
Moderna slides 2.42% today

Highlights

Moderna beat Q1 2026 revenue expectations but reported a wider GAAP net loss of $1.34 billion amid ongoing portfolio expansion.
Investors are awaiting an FDA decision on Moderna's mRNA flu vaccine in August 2026 while monitoring pipeline and regulatory milestones.
The stock faces short- and medium-term selling pressure, with bearish momentum signals prevailing but potential for an upward move within a $45.61 to $48.98 range.

Pipeline and regulatory updates drive sentiment amid broad selling pressure

Moderna reported a Q1 2026 revenue beat but posted a wider GAAP net loss of $1.34 billion as the company continued its transition toward a broader portfolio of mRNA-based vaccines and therapeutics. Investors monitored developments related to the pipeline and regulatory milestones, including an upcoming FDA decision on the flu vaccine expected in August 2026. Volatility followed renewed attention to infectious disease threats and a $770 million settlement gain for Roivant, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes persistent selling pressure for Moderna as price action stays below short- and medium-term moving averages. He highlights the wide Q1 net loss and the company’s dependence on pipeline approvals, cautioning that volatility and bearish momentum outweigh any near-term optimism. Kharitonov sees intraday technicals confirming a dominant seller presence despite oversold readings, suggesting market confidence remains low. The current sideways scenario reflects deep uncertainty until clear positive catalysts emerge. "Sustained losses and reliance on future breakthroughs make MRNA vulnerable to further declines if support at $45.61 fails," he says.

Viktoras Karapetjanc, expert at Traders Union, views Moderna’s long-term structure as fundamentally strong despite short-term softness. He sees a solid revenue performance and pipeline diversification as key to future growth, particularly with the FDA decision and settlement gains boosting sentiment. Karapetjanc believes four weekly Buy signals offer a bullish setup and expects a breakout above $48.98 to trigger further upside. He sees the current consolidation as a constructive base-building phase. "With fundamentals improving and technical signals aligning, the bullish structure remains intact and further growth is likely," he asserts.

Jainam Mehta, market strategist, observes that MRNA’s price action sits at a tactical juncture, with momentum negative yet oversold oscillators hinting at a possible rebound. He highlights divergence between short-term indicators and longer-term support above the MA-200. Mehta sees potential for a contrarian long entry if price holds above $45.61 and volatility stays low. "A break above resistance at $48.98 could spark momentum buying, but a failed hold may invite fresh downside," he cautions.

Bearish momentum prevails as oversold signals suggest rebound risk

Momentum indicators for MRNA are predominantly bearish on the daily chart. The MACD shows selling pressure, supported by the ADX indicating a weak trend. RSI and CCI are neutral-to-slightly-oversold, while the Stochastic RSI signals a potential technical rebound. Bull/Bear Power shows sellers are dominant intraday and that the condition is oversold, while the Awesome Oscillator is negative, supporting the short-term bearish outlook. Price action remains near the lower part of the daily range with volatility at 2.90%, as downside momentum persists in alignment with short-term indicator signals despite signs of divergence from oversold oscillators.

Earlier, analysts noted that while Moderna faced ongoing short- and medium-term bearish momentum, supportive long-term signals and positive pipeline developments left room for sentiment improvement. The latest analysis reinforces this view, highlighting that any sustained move above the $48.98 technical threshold could trigger near-term upside despite prevailing volatility and caution around regulatory catalysts.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.